Xenetic Biosciences Inc (XBIO)

Feb 07, 2025

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference - ACCESS Newswire

Feb 07, 2025

Jan 30, 2025

Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Up 1,920.0% in January - Defense World

Jan 30, 2025

Jan 26, 2025

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform - ACCESS Newswire

Jan 26, 2025

Jan 25, 2025

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - ACCESS Newswire

Jan 25, 2025

Jan 21, 2025

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - ACCESS Newswire

Jan 21, 2025

Jan 16, 2025

XBIOW (Xenetic Biosciences) Operating Income : $-4.36 Mil (TTM As of Sep. 2024) - GuruFocus.com

Jan 16, 2025

Jan 13, 2025

XBIOW (Xenetic Biosciences) Dividend Yield % : 0.00% (As of Jan. 13, 2025) - GuruFocus.com

Jan 13, 2025

Jan 11, 2025

XBIOW (Xenetic Biosciences) Cash Flow from Financing : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com

Jan 11, 2025

Dec 27, 2024

Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Drops By 93.8% - Defense World

Dec 27, 2024

Dec 17, 2024

Xenetic Biosciences Advances Revolutionary DNase Cancer Treatment Platform with UVA Partnership - StockTitan

Dec 17, 2024

Dec 16, 2024

Xenetic Biosciences Extends Breakthrough Cancer Research Program with UVA Through 2025 - StockTitan

Dec 16, 2024

Dec 13, 2024

Xenetic Biosciences shareholders elect directors, approve auditor By Investing.com - Investing.com UK

Dec 13, 2024

Dec 06, 2024

Xenetic and PeriNess partner for cancer treatment trials By Investing.com - Investing.com Canada

Dec 06, 2024

Dec 05, 2024

Xenetic and PeriNess partner for cancer treatment trials - Investing.com

Dec 05, 2024

Dec 05, 2024

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program - AccessWire

Dec 05, 2024

Dec 04, 2024

Xenetic Biosciences (STU:3XB0) Momentum Rank : 8 (As of Dec. 04, 2024) - GuruFocus.com

Dec 04, 2024

Nov 30, 2024

Xenetic Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 30, 2024

Nov 29, 2024

Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Down 43.2% in November - Defense World

Nov 29, 2024

Nov 24, 2024

HC Wainwright Reiterates Neutral Rating for Xenetic Biosciences (NASDAQ:XBIO) - Defense World

Nov 24, 2024

Nov 22, 2024

Xenetic Bio's DNase I Shows Breakthrough in Colorectal Cancer Treatment Efficacy | XBIO Stock News - StockTitan

Nov 22, 2024

Nov 21, 2024

XBIOXenetic Biosciences, Inc. Latest Stock News & Market Updates - StockTitan

Nov 21, 2024

Nov 21, 2024

Xenetic presents preclinical data on DNase I with CAR T cells in murine model - TipRanks

Nov 21, 2024

Nov 21, 2024

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis - AccessWire

Nov 21, 2024

Nov 21, 2024

Xenetic Bio's DNase I + CAR T Cell Therapy Shows Breakthrough in Melanoma Treatment | XBIO Stock News - StockTitan

Nov 21, 2024

Nov 15, 2024

Xenetic Biosciences Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 15, 2024

Nov 13, 2024

Xenetic reports Q3 EPS (28c) vs. (69c) last year - TipRanks

Nov 13, 2024

Nov 13, 2024

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results - AccessWire

Nov 13, 2024

Nov 13, 2024

Xenetic Bio Q3: R&D Costs Drop 64% as DNase Cancer Program Advances | $6.8M Cash | XBIO Stock News - StockTitan

Nov 13, 2024

Nov 13, 2024

Xenetic Biosciences: Q3 Earnings Snapshot - Houston Chronicle

Nov 13, 2024

Nov 12, 2024

Xenetic presents preclinical data on DNase platform technology - TipRanks

Nov 12, 2024

Nov 12, 2024

Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models - Oil City Derrick

Nov 12, 2024

Nov 12, 2024

Xenetic's DNase I Breakthrough Boosts Cancer Immunotherapy Efficacy in Preclinical Study | XBIO Stock News - StockTitan

Nov 12, 2024

Nov 09, 2024

Xenetic Biosciences Extends Research Collaboration with The Scripps Research Institute - Defense World

Nov 09, 2024

Nov 07, 2024

Xenetic extends research collaboration with Scripps Research Institute - TipRanks

Nov 07, 2024

Nov 07, 2024

Xenetic Biosciences Expands Collaboration for Cancer Treatment - TipRanks

Nov 07, 2024

Nov 07, 2024

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform - AccessWire

Nov 07, 2024

Nov 07, 2024

Pure Oil & Gas Secures $6M Funding, Reports 1,031% Production Surge in Q3 - StockTitan

Nov 07, 2024

Nov 01, 2024

Xenetic Biosciences announces board member changes By Investing.com - Investing.com Australia

Nov 01, 2024

Oct 31, 2024

Xenetic Biosciences announces board member changes - Investing.com India

Oct 31, 2024

Oct 26, 2024

Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Grows By 460.0% - Defense World

Oct 26, 2024

Oct 22, 2024

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 - AccessWire

Oct 22, 2024